6a57d64841594d5075e86a70-mp3
Jul 15, 2026 22:38
· 20:00
· English
· Whisper Turbo
· 5 بلندگوها
اين رونوشت فردا تموم ميشه
ارتقا برای ذخیرهسازی دائمی →
نمایش فقط
0:02
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I just jump right in.
0:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
The reason I'm bringing it up is like,
0:05
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know,
0:05
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
even in these meetings,
0:07
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
which are like all informed people and in the guidelines and things,
0:10
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
like it does, it impacts the community because like,
0:13
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know,
0:14
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's hard for me as Joe Blow,
0:16
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
community doc,
0:17
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
even though you guys are doing it,
0:19
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you're my offer, you can get away with it.
0:20
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I'm like, you know,
0:21
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I wonder when are they going to update these things to make it seem more legit.
0:26
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I don't know if that makes sense,
0:27
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
but since that's the case,
0:29
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I'm going to jump right in.
0:31
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Just pointing it out.
0:32
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
For sure,
0:34
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
yeah.
0:34
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And this is labeled stuff,
0:36
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
so we're going to get into discussion of some of the data.
0:40
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
No,
0:41
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's good,
0:42
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's good.
0:43
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Yeah,
0:44
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
please do.
0:44
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
All right,
0:46
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
next slide.
0:47
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Yeah, okay,
0:47
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
so here's the discussion slides for the first time.
0:51
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
What has been your experience with initiating step -up dosing in the community
0:55
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
versus referring to that?
1:00
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I screwed up.
1:01
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Yeah,
1:02
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
no.
1:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I mean,
1:04
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know, so it's interesting with this group,
1:07
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
actually.
1:07
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
You know,
1:08
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
honestly, I feel like I...
1:11
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
have been very heavy in a managed care world,
1:14
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and I realize you three are pharmacists,
1:17
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and you know,
1:19
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you have some managed care problems,
1:22
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
but relatively limited,
1:23
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and FCS does not have as heavy a managed care population
1:27
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
as we do,
1:29
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and like,
1:30
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I don't know, I'm curious to hear more from you about FCS and what they're doing in managed care,
1:34
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
but historically they are not a heavy,
1:37
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know, managed care friendly entity.
1:41
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
as opposed to you know locally you know it's really us
1:46
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and like you know there's a few other entities that are starting
1:50
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
to get their toes in it but I fell into this world and now I feel I
1:55
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
weirdly became like a weird expert in it which is surprising even to me but
1:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's a big issue because you know in places where
2:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you're talking about like
2:05
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
costs of care and efficiency and people who have financial
2:09
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
limitations, you know,
2:11
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
these are major concerns,
2:13
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
obviously.
2:14
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And so,
2:16
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know, referring to an academic center is a burden on the patients,
2:20
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's a burden on the system,
2:22
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and it's not easy.
2:24
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And so if we're going to be bringing these treatments up,
2:27
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
we feel strongly they need to be done in an efficient
2:31
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
but safe way.
2:32
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
For sure.
2:35
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
limitations there.
2:36
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So, for example,
2:37
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
certain TGH pharmacists have
2:41
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
cheaped out and not stocked Tosi at their hospital.
2:44
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And,
2:46
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
no,
2:47
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
but like, you know,
2:48
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
that's an issue for us.
2:49
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So even though TGH is five minutes from my office,
2:52
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know,
2:53
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I can't reliably trust them to be there to back me up,
2:58
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
which is unfortunate.
2:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And Moffitt is not...
3:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
very friendly to a lot of the plans and has its own issues.
3:07
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And so,
3:08
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know, sometimes it feels like we're out on an island like
3:12
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
fending it for ourselves.
3:13
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
You know,
3:16
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I'm starting the meeting by attacking the pharmacist and then attacking the
3:20
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
hospital system.
3:20
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But like, you know,
3:22
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I, you know.
3:23
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
You tell me what it is.
3:25
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But these are the frustrations in my life.
3:28
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And,
3:28
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know,
3:29
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's a real thing.
3:33
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Which to this question,
3:34
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it limits you from being able to initiate.
3:36
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
It's a major hurdle because,
3:40
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know,
3:41
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you can do it.
3:43
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
It's not that you can't do it.
3:45
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But if you're trying to do it in a way that is efficient
3:49
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and patient -friendly and just makes sense,
3:54
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's almost impossible.
3:56
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Respectives,
3:58
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
downs.
3:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Yeah, I'm going to hear from this.
4:00
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Yes, that's what I want to hear.
4:02
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So our relationship with managed care is
4:06
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
pod -dependent.
4:06
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So in certain areas where managed care is much more abundant,
4:10
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
we would have relationships for it.
4:12
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But I think the biggest thing to think about is that conceptually,
4:15
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
we approach it at an FCS level with
4:19
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
managed care organizations.
4:20
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So we try to find a middle ground in terms of what the philosophies are.
4:24
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Thinking about managed care and HMOs,
4:26
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
they're really thinking about cost.
4:28
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
structures not necessarily sacrificing quality of care
4:32
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
but they're definitely valuing the present as opposed to the future and so
4:37
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
there's always an open discussion about what it is that we're willing to do to be able to provide good
4:41
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
quality of care for our patients and then at the end of the day what we need
4:45
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
for overall long -run efficacy.
4:47
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And I think there are a lot of managed care organizations that are starting to warm up to
4:51
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
that idea.
4:51
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But understanding that a lot of payers are operating
4:56
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
five to ten years behind on their sciences.
5:00
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
the processes,
5:01
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
especially as an oncology.
5:02
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
You know,
5:04
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
HMOs and managed care really found its breadth within primary
5:08
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
care, the breadth of general medical medicine diseases.
5:12
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Lo and behold,
5:13
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
as you get older,
5:14
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
cancer is part of it,
5:16
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and I don't think that philosophy has ever really transferred very well.
5:19
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
care, but I think that's where value -based care really
5:23
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
does come in.
5:24
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I usually say that's quality divided by cost,
5:27
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and I think there is a middle ground and an opportunity for an industry to
5:31
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
really think about how to restructure the next set of clinical trials
5:36
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and FDA labels and approvals to be able to meet those needs.
5:40
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Because industry care is not going to go away in terms of that,
5:43
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
so I usually say that it's a multi -stakeholder special that we've
5:47
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
had.
5:49
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
We bring in our hospital partners to really partner that discussion.
5:52
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So are you?
5:54
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
You are doing step -up dosing in the community setting?
5:58
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
You are,
5:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
yeah, okay.
5:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Yeah, we've been probably over,
6:01
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
across all of our sites,
6:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
we've probably had about 800 or 900 step
6:07
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
-up dosing.
6:07
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Wow.
6:08
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
Combination right now.
6:12
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I think right now we try to adhere to the label as much as possible.
6:15
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
That's really actually right here.
6:23
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Correct.
6:24
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But you know,
6:24
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I think the rate limiting step is really,
6:27
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
to your point earlier,
6:29
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
is finding a really good,
6:30
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
motivated hospital partner to get a lot of help from an AD agent.
6:33
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Because all of us know that as
6:38
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
soon as you light the fire,
6:39
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you need to make sure you have a good system to keep the patient safe.
6:44
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Even if you're able to keep the majority of patients outpatient,
6:48
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
10 % of them are going to get admitted at some point in time anyway.
6:52
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So if you do enough of these,
6:53
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it lights the bulb for both payers as well as hospital
6:58
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
partners too.
6:58
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Because while we think about it really from an outpatient perspective,
7:02
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
looking out for our hospital partners is important because a lot of our hospital
7:06
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
partners may not necessarily do oncology.
7:11
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And so to your point earlier about Chelsea being stocked,
7:14
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
sometimes it's a decision internally amongst hospitals to
7:18
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
decide, well,
7:20
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's hard for us to really justify,
7:21
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
depending on how many patients we're treating,
7:24
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
to be able to harbor that cost.
7:25
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And how does managed care treat inpatient
7:30
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
hospitalization,
7:30
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
even if it's considered elective,
7:33
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
which is not really it's elective.
7:34
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Even though it's packaged and served,
7:36
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's an elective admission.
7:39
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Get them in office.
7:40
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
We all know at the table,
7:42
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
these patients are not really hot.
7:44
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So those are the fundamental breaks and barriers
7:48
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
that I think really put down and limit the
7:52
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
adoption of bispecific therapy or cell therapy in general.
7:55
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I think the biggest thing is understanding that it all comes down to money.
7:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
It has nothing really to do with patient care.
8:04
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
I do think the finances of
8:08
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
it are playing a bigger role than people like to talk about because
8:12
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
there's so many people impacted from the pharmaceutical side,
8:16
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
from the managed care side,
8:17
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
from the hospital system side.
8:19
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And there's this dance happening right now that is very complicated.
8:23
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And I feel like I'm in the middle of the ballroom just looking around.
8:27
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And I think that...
8:32
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
you know, some of the managed care plans just hope it goes away and fizzles out,
8:36
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
which is clearly not going to happen.
8:37
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And the hospital systems are like trying to
8:42
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
stall until they can figure out how to make it make financial sense.
8:45
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And then obviously the pharmaceutical industry is trying to rush things along
8:49
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
as fast as they can.
8:50
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So,
8:51
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
you know, it's like a tug of war of trying to speed things up and slow things down.
8:55
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
But at the end of the day,
8:56
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
it's a train and it's going to keep on moving.
8:58
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So this is coming.
9:00
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And, you know,
9:01
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
from my perspective,
9:02
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
as somebody who lives and breathes managed care,
9:06
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
you know,
9:07
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
and wants to be able to provide high -level,
9:10
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
efficient care,
9:11
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
you know,
9:12
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
I feel like it's better that we come up with a plan that works
9:16
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
for the patients, works for the hospital system,
9:19
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
so everybody can get on the same page,
9:21
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
so that we can do this efficiently in the community.
9:25
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
You know, we're very thoughtful in my practice,
9:27
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
to be honest.
9:28
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
We're unusually considerate to all these factors.
9:31
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
But we're a small mom and pop organization compared to
9:35
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
the big players.
9:36
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And we were,
9:39
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
you know, we have roots in managed care.
9:42
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
But that's very unusual.
9:43
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
There's very few practices like us.
9:45
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
Most practices and most oncologists have very little experience in this
9:49
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
arena. And they are much less thoughtful in these things.
9:53
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And I think if people don't come up with a better systemic
9:57
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
plan,
9:58
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
you know,
10:00
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
going to pay for that in the long run so to me it seems like a no -brainer
10:04
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
to come up with a things like adjusting the labels
10:08
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
like people like Moffitt should point out that like oh
10:12
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
we do this all outpatient even though the label says it's all inpatient
10:16
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
you know, they're getting that based off the studies you guys did,
10:19
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
whatever, 10 or 15 years ago,
10:21
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
even though now you're doing it on outpatient,
10:24
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
but then the community doctors,
10:26
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
myself included,
10:27
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
are nervous because if the package insert says that
10:31
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
even though you guys are not doing it,
10:32
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
it's hard,
10:33
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
you can get away with that,
10:34
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
you know, but it's nervous for a community doctor to go do that.
10:38
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
Is it just,
10:38
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
well that's just an example,
10:39
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
but, and then like the TGH is not stalking TOSI.
10:44
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
So we'll say,
10:44
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
TOSI will be able to be a baby,
10:48
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
I don't think they'll be able to spray them.
10:49
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
Right, well guess what, where TGH has an oncology practice,
10:52
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
they have TOSI very conveniently,
10:54
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
where it's their financial interest to do that,
10:56
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
and their community hospital.
10:58
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
They should ship TOSI at all,
10:59
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
that doesn't take too long.
11:01
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
If it was a patient care issue,
11:02
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
they would.
11:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Yeah.
11:04
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So there's two things to say to that.
11:07
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So one, I completely agree with you regarding the labeling.
11:10
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
I think the labeling makes a big difference.
11:11
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
Must,
11:12
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
should,
11:15
S…
Speaker 5 (6a57d64841594d5075e86a70-mp3)
hospitalize,
11:16
S…
Speaker 5 (6a57d64841594d5075e86a70-mp3)
must, you know,
11:16
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
there's like...
11:17
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
It makes a
11:22
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
big difference.
11:22
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
You know,
11:23
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
REMS program makes a big difference.
11:25
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
Myeloma bispecifics are the only bispecifics right now with the REMS program,
11:28
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
which adds another issue.
11:30
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
It's kind of interesting,
11:31
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
isn't it?
11:31
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
It is.
11:32
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
The REMS is a lower.
11:33
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
To me, the REMS is a lower.
11:36
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
It's operational,
11:37
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
but the FDA labeling definitely makes a big difference.
11:39
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And I think now,
11:42
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
another thing to talk about is just by specifics in general,
11:46
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
it's not just within heme space,
11:48
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
right? It's like solids,
11:50
S…
Speaker 5 (6a57d64841594d5075e86a70-mp3)
it's exploding.
11:51
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
In a matter of a few years,
11:52
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
it's going to be all,
11:53
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
like we're already doing clinical trials in a lot of solid tumors.
11:58
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So it's coming.
11:59
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So, you know,
12:00
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
we really need to start,
12:01
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
you know, thinking for hospitals to start thinking about Thosalizumab really from
12:05
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
a larger perspective because it's not just few agents,
12:08
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
like more patients are going to be having different,
12:11
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know.
12:11
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
therapies.
12:12
S…
Speaker 3 (6a57d64841594d5075e86a70-mp3)
Everybody's stalling this problem,
12:14
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
but we all know it's coming.
12:16
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
We all know it's coming.
12:17
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But I
12:25
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
think
12:30
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
this slide illustrates one of the biggest root causes
12:34
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
of what we're talking about right here.
12:35
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
The instance of CRS.
12:37
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
That's why we're having the considerations with the labeling.
12:41
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
We're having nervousness about treating in the community centers because of the rates of
12:45
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
CRS, which range anywhere from 46 to 79 %
12:49
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
in the main clinical trials that were put forward with this.
12:52
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
which didn't use TOSI,
12:53
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
but again,
12:54
S…
Speaker 4 (6a57d64841594d5075e86a70-mp3)
that's significant.
12:55
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
ICANN's rates of 3 to 11%,
12:58
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
so significant toxicities based on the registrational trials that
13:02
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
are out there, and that's what's driving a lot of this.
13:04
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So when you look at,
13:05
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
next slide, please.
13:06
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
When you look at some of the evolving
13:10
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
data that's coming out,
13:11
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
especially in the second -line therapy,
13:13
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
TEC3,
13:13
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
which looks at teclistimab and daritumumab in second -line therapy,
13:19
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
a large open -label trial demonstrating the benefits after first relapse.
13:23
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Progression -free survival with a secondaire of 83 % versus
13:27
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
29 % in the control arm.
13:29
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Overall survival,
13:30
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
again, 83 % versus 65%.
13:32
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So some good data of pushing this up earlier into therapy,
13:36
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
right, and really demonstrating the huge benefit of
13:40
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
these drugs.
13:41
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And I promise we'll get back to the discussion around CRS
13:45
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and side effects in the outpatient.
13:48
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
This will kind of set the table.
13:49
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So next slide.
13:50
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Looks at TEC9,
13:53
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
which was an abstract at ASCO this past year.
13:55
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Illustrates the improvements in progression -free survival and overall survival.
14:00
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
What took us to have is mild therapy and second -line therapy.
14:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And,
14:04
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know, 69 .8 % progression -free survival versus
14:09
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
26.
14:09
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Overall survival benefits as well.
14:12
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So significant here.
14:13
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I mean, look at the rates of CRS in this trial,
14:16
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
though. Again,
14:16
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
similar to what we saw in our trial.
14:18
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
earlier rates in that 66 percent TAL,
14:24
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
next slide please.
14:25
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
TAL3 is Tauquetimab with neritumumab and Zecamon therapy again
14:30
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
just furthering these results were presented earlier this year representing
14:34
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
that whether it's given in combination or given alone demonstrates really
14:39
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
impressive two -year progression for survival.
14:43
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So more and more data suggesting that these drugs need to be moved off
14:47
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
of fifth -line therapy and up earlier in therapy for these relapsed patients.
14:51
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
When you look at the CRS grades that were in
14:55
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
both the Taquatimab alone or in combination,
14:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
again,
14:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
right
15:00
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
down the middle of what we've seen overall next
15:04
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
slide and this just this slide just shows that graphically so why
15:10
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
why is it important because instead of 5 000 patients
15:14
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
that we're talking about it's 27 000 patients
15:18
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So five times the number of patients are eligible.
15:21
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
You're going to see more patients that potentially could benefit from this therapy that
15:25
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
is, again,
15:26
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
changing outcomes in this space.
15:28
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So it's really important that we try to figure out,
15:32
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
okay, now that we've seen that giving it earlier is better,
15:34
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
how do we do that?
15:35
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
How do we do that in a community setting?
15:37
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
We had a discussion earlier as we got started.
15:40
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
It's great if we do all this care in academic medical centers and patients
15:44
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
outside of those territories don't get therapy and
15:48
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
succumb to these outcomes.
15:50
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
We have to do better in this space.
15:51
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
We have to figure out how do we push this out.
15:54
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
And that's the whole thing for some discussion.
15:57
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So, another question for the group here,
16:00
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
and based on the initial data with bispecifics and second line,
16:03
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
where in the relapsed multiple myeloma treatment
16:08
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
landscape are you thinking about Ticlistamab and Telquivab
16:12
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
-based treatments?
16:13
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
I'll open it up for discussion.
16:15
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
Well,
16:17
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I mean, I think the major decision point is that are they CAR -T eligible or not?
16:21
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I think it's an important distinction in all of this,
16:24
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
because I think...
16:33
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
because we know that it's curative.
16:35
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Obviously,
16:37
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
the data looks extremely good from Majestic 3 and
16:41
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
how remission rates and whatnot.
16:42
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
We may come to a point in time where we will find that we
16:47
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
stopped therapy on some of these patients,
16:49
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
so they do fine.
16:51
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But I think that's kind of where the data still stands,
16:54
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
that you triage these patients appropriately between the two.
16:57
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But hands down with logistics issues,
17:00
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
vulnerabilities, access to care,
17:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
things like that,
17:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
that it certainly makes sense that you really consider these patients for my specific therapy.
17:08
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I'll add also that I think the number
17:12
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
of patients additionally per year is probably lower
17:16
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
than what we really think.
17:18
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
just partly because the quad therapy is actually good.
17:21
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And so I think what we find is that there's going to be fewer and
17:25
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
fewer of these patients that we're trying to see that transplant is less needed even
17:29
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
in the frontline setting now.
17:30
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And so how many of these patients will actually exist probably
17:35
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
remains to be said.
17:36
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
But knowing from the data that we have now and early consideration
17:40
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
of these products are really,
17:42
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
really important.
17:42
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
This is exploding.
17:46
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
So that pocket of
17:50
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
patients then is going to be...
17:54
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
Have you used the bispecifics in the second
17:58
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
line? I have,
17:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
yeah.
17:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Okay.
18:00
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And to point about managed care and things like that,
18:03
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
you know, the patients that we're treating at the community are not in the registry studies.
18:07
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
The last patient that I treated with teclisimab in Dero was
18:11
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
91 years old.
18:12
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
She outlived all of her friends,
18:15
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
family,
18:15
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and neighbors,
18:17
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
and so forth.
18:18
S…
Speaker 2 (6a57d64841594d5075e86a70-mp3)
Wow.
18:18
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
She's still very sprightly and knows her care,
18:21
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
all of her medications really well,
18:23
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
but she just
18:26
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So those are the patients that we treat in the community that will
18:30
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
never make those registration slides.
18:33
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
They all have CKD,
18:34
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
they all have coronary artery disease.
18:36
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Their EF might be less than 30%,
18:39
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
but they're chugging along just fine.
18:40
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So understanding,
18:43
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
I think these are things that J &J and others know from me very well at
18:47
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
this point, is that community -based trials are very,
18:50
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
very important.
18:51
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Because that's really the proof of concept.
18:54
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
to understand how can you really implement this community and provide confidence.
18:59
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And understanding,
19:00
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
are you allowing a patient to get treated on trial that has
19:05
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
phase one support?
19:06
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Do they actually,
19:07
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
are their office built into a hospital?
19:10
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Do they have a motivated hospital?
19:13
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Do they even have neurologists that are available?
19:16
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
That's why I think there's a lot of value in having a community -based
19:20
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
trial as a perfect concept.
19:22
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And that's really what payers are really looking at.
19:24
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
They look to the model of what you have established within an
19:28
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
industry in these major randomized clinical trials and saying,
19:31
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
that's the standard.
19:32
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
So there's this artificial barrier to say,
19:35
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
okay,
19:36
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
for this bispecific patient,
19:38
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
if you want to actually undergo and treat these patients long -term,
19:41
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
do you have this?
19:42
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
Do you have this?
19:43
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And some of this we self -impose at FCS because we don't want to necessarily
19:47
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
treat patients with bispecific therapy unless they meet a minimum
19:51
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
standard that we can offer services.
19:54
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
And at the end of the day,
19:56
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
with bispecific therapy,
19:57
S…
Speaker 1 (6a57d64841594d5075e86a70-mp3)
it's not just about treating the patient and making sure you
این رونوشت توسط AI (شناسایی خودکار گفتار) تولید شد. ممکن است حاوی خطا باشد — برای استفادهٔ حیاتی با صدای اصلی بررسی کنید. سیاست هوش مصنوعی
خلاصه
برای تولید خلاصهای از این رونوشت از هوش مصنوعی ، خلاصه را فشار دهید.
خلاصه کنم...
از هوش مصنوعی در مورد این رونوشت بپرسید
در این روش، هر سؤالی که در مورد این رونوشت پرسیده شود، هوش مصنوعی بخشهای مربوطه را پیدا کرده و پاسخ میدهد.